(E)-4-(dimethylamino)-2′,3′,4′-trimethoxychalcone | 127034-25-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-4-(dimethylamino)-2′,3′,4′-trimethoxychalcone
• 英文别名: 1-(2,3,4-trimethoxyphenyl)-3-[4-(dimethylamino)phenyl]prop-2-en-1-one；4-dimethylamino-2',3',4'-trimethoxychalcone；(E)-3-[4-(dimethylamino)phenyl]-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one
• CAS: 127034-25-7
• 化学式: C₂₀H₂₃NO₄
• 分子量: 341.407
• InChiKey: JAUIRHADPPXRBC-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-4-(dimethylamino)-2′,3′,4′-trimethoxychalcone 在 磺酰氯 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 反应 1.0h， 以23%的产率得到α-chloro-4-dimethylamino-2',3',4'-trimethoxychalcone
  参考文献：
  名称：

  Chalcones: a new class of antimitotic agents

  摘要：

  A series of chalcones was evaluated as antimitotic agents. One of these, (E)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl-2-pr open- 1-one) (73), was found to be an effective antimitotic agent at a concentration of 4 nM in an in vitro HeLa cell test system. When evaluated in experimental tumor models in vivo, this compound exhibited antitumor activity against L1210 leukemia and B16 melanoma.

  DOI：

  10.1021/jm00169a021
• 作为产物：
  描述：

  3',4',5'-三甲氧基苯乙酮 、 对二甲氨基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以59%的产率得到(E)-4-(dimethylamino)-2′,3′,4′-trimethoxychalcone
  参考文献：
  名称：

  2'-Substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis

  摘要：

  A series of 2'-substituted chalcone derivatives has been found to show potent inhibition of the production of IL-1beta from human peripheral blood monocytes stimulated with lipopolysaccharide (LPS), with IC50 values in the 0.2-5.0-muM range. Some members of the series have also shown inhibition of septic shock induced in mice by injection of LPS, although with low potency. Qualitative structure-activity relationships have shown that the enone is required for activity, which may be mediated by conjugate addition of a biological nucleophile to the chalcone. Electron-poor aromatic rings beta to the ketone give enhanced potency. Although electronic effects in the other ring (directly attached to the ketone) are minimal, this ring must possess an ortho substituent for good activity without cytotoxicity, suggesting a degree of selectivity which would not be expected for simple, nonspecific alkylating agents.

  DOI：

  10.1021/jm00062a016

文献信息

• Antimalarial Alkoxylated and Hydroxylated Chalones:  Structure−Activity Relationship Analysis
  作者：Mei Liu、Prapon Wilairat、Mei-Lin Go

  DOI：10.1021/jm0101747

  日期：2001.12.1

  among the active compounds. Hydroxylated chalcones were less active than the corresponding alkoxylated analogues. When evaluated in vivo, 8 and 208 were comparable to chloroquine in extending the lifespan of infected mice. Multivariate data analysis showed that in vitro activity was mainly determined by the properties of ring B. Quantitative structure-activity relationship models with satisfactory predictive

  合成在环B上具有2'，3'，4'-三甲氧基，2'，4'-二甲氧基，4'-甲氧基，4'-乙氧基，2'，4'-二羟基和4'-羟基的邻苯二甲酰并在[3H]次黄嘌呤摄取测定中针对恶性疟原虫（K1）进行了体外评估。另一个环A是具有不同亲脂性的给电子或吸电子取代基的喹啉，吡啶，萘或苯环。三甲氧基6和27，二甲氧基7，8，29和甲氧基31类似物具有良好的体外活性（IC（50）<5 microM）。在活性化合物中很好地代表了3-喹啉基环A衍生物。羟基查耳酮的活性低于相应的烷氧基化类似物。在体内评估时，8和208在延长被感染小鼠的寿命方面与氯喹相当。多变量数据分析表明，体外活性主要取决于环B的特性。使用对潜在结构的投影，获得了各种B环查耳酮具有令人满意的预测能力的定量构效关系模型。提出了一个具有良好可预测性的模型，用于19个活动查尔肯。尺寸和疏水性被确定为关键参数。
• Antileishmanial Chalcones:  Statistical Design, Synthesis, and Three-Dimensional Quantitative Structure−Activity Relationship Analysis
  作者：Simon Feldbæk Nielsen、Søren Brøgger Christensen、Gabriele Cruciani、Arsalan Kharazmi、Tommy Liljefors

  DOI：10.1021/jm980410m

  日期：1998.11.1

  coefficient plots indicate that steric interactions between the chalcones and the target are of major importance for the potencies of the compounds. A comparison of the coefficient plots for the antileishmanial effect and the lymphocyte-suppressing activity discloses significant differences which should make it possible to design chalcones having a high antileishmanial activity without suppressing the

  已经合成了大量取代的查耳酮，并测试了其对抗盲肠和淋巴细胞的抑制活性。使用统计方法设计了查耳酮的一个子集。通过使用GRID / GOLPE方法，使用67种化合物（抗肠蠕动活性）和63种化合物（抑制淋巴细胞的活性）对训练组和9种化合物作为外部验证组进行了3D-QSAR分析。在GOLPE中实施的具有区域选择功能的智能区域定义程序将变量数量减少到大约1300个，从而产生了高质量的3D-QSAR模型（​​淋巴细胞抑制模型，R2 =0。90，Q2 = 0.80；反兽皮模型，R2 = 0.73，Q2 = 0.63）。系数图表明，查耳酮与靶标之间的空间相互作用对于化合物的效能至关重要。抗菌剂作用和淋巴细胞抑制活性的系数图的比较揭示了显着的差异，这应该使设计具有高抗菌剂活性的查耳酮成为可能，而又不抑制淋巴细胞的增殖。
• Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
  申请人：Statens Serum Institute

  公开号：US20030065039A1

  公开（公告）日：2003-04-03

  The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.

  该发明涉及使用1,3-双芳基-丙-2-烯-1-酮（香豆素）、1,3-双芳基-丙酮-1-酮（二氢香豆素）和1,3-双芳基-丙-2-炔-1-酮制备用于治疗或预防多种严重疾病的药物组合物，包括i）与炎症细胞因子有害作用相关的疾病，ii）涉及幽门螺旋杆菌感染的疾病，iii）涉及病毒感染的疾病，iv）肿瘤性疾病，v）由微生物或寄生虫引起的疾病。该发明还涉及新型香豆素和二氢香豆素（特别是烷氧基取代变体），其具有有利的取代模式，对其作为药物物质的效果，以及制备它们的方法，以及包含新型香豆素的药物组合物。此外，本发明涉及一种用于分离利什曼氏弓形虫富马酸还原酶的方法，以及用于选择上述目的的有效化合物的QSAR方法。
• Novel use of compounds of the chalcones class
  申请人：——

  公开号：US20020143064A1

  公开（公告）日：2002-10-03

  Process for inhibiting vascularization of a tumor mass comprising administering, in an amount effective to inhibit vascularization, at least one chalcone of formula (I): 1 wherein: R is chosen from a hydrogen atom, a methyl group, an ethyl group, a chlorine atom, and a bromine atom, A is an NR 1 R 2 group, wherein R 1 and R 2 , which may be identical or different, are each chosen from a methyl group and an ethyl group, and n is an integer equal to 2 or 3.

  一种抑制肿瘤组织血管生成的处理过程，包括给予至少一种化合物，其有效抑制血管生成，该化合物为式（I）至少一种香豆素：1其中：R选自氢原子，甲基基团，乙基基团，氯原子和溴原子，A是NR1R2基团，其中R1和R2，可以相同也可以不同，分别选自甲基基团和乙基基团，n是等于2或3的整数。
• Palladium-Catalyzed Decarboxylative Arylation of Benzoylacrylic Acids toward the Synthesis of Chalcones
  作者：Yuto Unoh、Koji Hirano、Tetsuya Satoh、Masahiro Miura

  DOI：10.1021/jo400716e

  日期：2013.5.17

  It has been found that readily available 3-benzoylacrylic acids undergo palladium-catalyzed decarboxylative arylation with arylboronic acids in the presence of a copper salt oxidant to produce chalcone derivatives. The decarboxylative arylation could also be achieved using aryl halides as the alternative aryl source to expand the applicable scope.